Axa S.A. Savara Inc Transaction History

Axa S.A.

$32.2 Billion
Q4 2024

A detailed history of Axa S.A. transactions in Savara Inc stock. As of the latest transaction made, Axa S.A. holds 1,049,775 shares of SVRA stock, worth $2.95 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

1,049,775

Previous 1,051,432 0.16%

Holding current value

$2.95 Million

Previous $4.46 Million 27.73%

% of portfolio

0.01%

Previous 0.01%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	SELL	$2.94 - $4.07 $4,871 - $6,743	-1,657 Reduced 0.16%	1,049,775 $3.22 Million
Q3 2024 Nov 14, 2024	BUY	$3.96 - $5.07 $1,176 - $1,505	297 Added 0.03%	1,051,432 $4.46 Million
Q2 2024 Feb 25, 2025	BUY	$3.66 - $5.34 $4,977 - $7,262	1,360 Added 0.13%	1,051,135 $4.24 Million
Q2 2024 Aug 14, 2024	SELL	$3.66 - $5.34 $1.02 Million - $1.49 Million	-279,300 Reduced 20.99%	1,051,135 $4.24 Million
Q1 2024 May 15, 2024	SELL	$4.19 - $5.59 $1.75 Million - $2.33 Million	-417,238 Reduced 23.87%	1,330,435 $6.63 Million
Q4 2023 Jul 16, 2024	BUY	$3.18 - $4.9 $1.33 Million - $2.04 Million	417,238 Added 31.36%	1,747,673 $8.21 Million
Q4 2023 Feb 14, 2024	SELL	$3.18 - $4.9 $134,434 - $207,147	-42,275 Reduced 2.36%	1,747,673 $8.21 Million
Q3 2023 Nov 14, 2023	SELL	$2.97 - $3.88 $1.47 Million - $1.93 Million	-496,455 Reduced 21.71%	1,789,948 $6.77 Million
Q2 2023 Aug 14, 2023	SELL	$1.69 - $3.24 $917,546 - $1.76 Million	-542,927 Reduced 19.19%	2,286,403 $7.29 Million
Q1 2023 May 15, 2023	SELL	$1.6 - $2.82 $925,691 - $1.63 Million	-578,557 Reduced 16.98%	2,829,330 $5.52 Million
Q4 2022 Feb 14, 2023	SELL	$1.11 - $1.64 $20,344 - $30,057	-18,328 Reduced 0.53%	3,407,887 $5.28 Million
Q3 2022 Feb 14, 2023	BUY	$1.36 - $1.88 $20,040 - $27,703	14,736 Added 0.43%	3,426,215 $4.87 Million
Q3 2022 Nov 14, 2022	BUY	$1.36 - $1.88 $20,040 - $27,703	14,736 Added 0.43%	3,426,215 $5.31 Million
Q2 2022 Feb 14, 2023	SELL	$1.1 - $1.58 $72,988 - $104,837	-66,353 Reduced 1.91%	3,411,479 $5.19 Million
Q2 2022 Aug 15, 2022	SELL	$1.1 - $1.58 $72,988 - $104,837	-66,353 Reduced 1.91%	3,411,479 $5.19 Million
Q1 2022 Feb 14, 2023	BUY	$1.05 - $1.36 $54,197 - $70,199	51,617 Added 1.51%	3,477,832 $4.56 Million
Q1 2022 May 13, 2022	BUY	$1.05 - $1.36 $38 - $50	37 Added 0.0%	3,477,832 $4.56 Million
Q4 2021 Feb 14, 2022	BUY	$1.04 - $1.34 $428,990 - $552,737	412,491 Added 13.46%	3,477,795 $4.31 Million
Q3 2021 Nov 15, 2021	BUY	$1.18 - $1.64 $133,427 - $185,441	113,074 Added 3.83%	3,065,304 $4.23 Million
Q2 2021 Aug 13, 2021	SELL	$1.51 - $2.29 $338,529 - $513,399	-224,192 Reduced 7.06%	2,952,230 $5.02 Million
Q1 2021 May 14, 2021	BUY	$1.17 - $2.33 $1.5 Million - $2.98 Million	1,280,868 Added 67.57%	3,176,422 $6.61 Million
Q4 2020 Feb 12, 2021	BUY	$1.0 - $1.47 $491,035 - $721,821	491,035 Added 34.96%	1,895,554 $2.18 Million
Q3 2020 Nov 13, 2020	SELL	$1.09 - $2.21 $8,412 - $17,056	-7,718 Reduced 0.55%	1,404,519 $1.53 Million
Q2 2020 Aug 14, 2020	BUY	$1.8 - $3.05 $128,233 - $217,285	71,241 Added 5.31%	1,412,237 $3.52 Million
Q1 2020 May 15, 2020	BUY	$1.91 - $4.08 $2.56 Million - $5.47 Million	1,340,996 New	1,340,996 $2.84 Million

Others Institutions Holding SVRA

# of Institutions

141

Shares Held

158M

Call Options Held

55.6K

Put Options Held

600

View Full List

About Savara Inc

Ticker SVRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 114,043,000
Market Cap $320M
Description
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.

More about SVRA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Axa S.A., based on Form 13F filings with the SEC.

News

Stay updated on Axa S.A. with notifications on news.

Account